Testosterone News and Research

Latest Testosterone News and Research

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.

9 Mar 2011

Parkinson's disease medication turns on critical gene, protects brain cells

In a major breakthrough in the battle against Parkinson's disease, researchers at the University of Colorado School of Medicine have discovered a drug that stops the progression of the degenerative illness in mice and is now being tested in humans.

9 Mar 2011

Study examines link between voice pitch and perceived infidelity

When choosing a partner, women believe the lower the man's voice, the more likely he's going to cheat. Conversely, men think a woman with a higher voice is more likely to be unfaithful, researchers have found.

5 Mar 2011

Biosante to purchase $25.1 million shares of common stock in registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $25.1 million of securities in a registered direct offering.

5 Mar 2011

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Dentists need to take a closer look at potential hazards of exposing patients to zinc, a common ingredient of many dental products, according to a report by Amar Patel, DDS, resident and colleagues at the University of Maryland Dental School in the March/April 2011 issue of the journal General Dentistry.

4 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo Pharmaceuticals announced that FORTESTA Gel – recently approved by the U.S. Food and Drug Administration for the treatment of low testosterone, or 'Low T' in adult males – is now available by prescription in pharmacies across the country.

3 Mar 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.

24 Feb 2011

Skeleton regulates fertility in males, but not females

Researchers at Columbia University Medical Center have discovered that the skeleton acts as a regulator of fertility in male mice through a hormone released by bone, known as osteocalcin.

17 Feb 2011

Molecular explanation to higher tendency for autism among males

George Washington University researcher, Dr. Valerie Hu, Professor of Biochemistry and Molecular Biology, and her team at the School of Medicine and Health Sciences, have found that male and female sex hormones regulate expression of an important gene in neuronal cell culture through a mechanism that could explain not only higher levels of testosterone observed in some individuals with autism, but also why males have a higher incidence of autism than females.

17 Feb 2011

Early balding linked to prostate cancer: Study

Balding early in life causes grief for many men and now new research will cause even more alarm. Researchers have found that early balding may be liked to prostate cancer.

16 Feb 2011

Men going bald at young age more likely to develop prostate cancer in later life

Men who start to lose hair at the age of 20 are more likely to develop prostate cancer in later life and might benefit from screening for the disease, according to a new study published online in the cancer journal, Annals of Oncology today.

15 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

BioSante Pharmaceuticals, today announced positive safety data in its ongoing LibiGel Phase III clinical development program.

13 Feb 2011

New study: Testosterone administration leads to significant reduction in mind reading

A new study from Utrecht and Cambridge Universities has for the first time found that an administration of testosterone under the tongue in volunteers negatively affects a person's ability to 'mind read', an indication of empathy. The findings are published this week in the journal Proceedings of the National Academy of Sciences.

9 Feb 2011

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Longer life with osteoporosis therapy: Study

In a new breakthrough, Australian scientists have identified the “remarkable” life-extending properties of an osteoporosis treatment. The research is published in the Journal of Endocrinology and Metabolism on Thursday.

3 Feb 2011

Testosterone News and Research

Latest Testosterone News and Research

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Parkinson's disease medication turns on critical gene, protects brain cells

Study examines link between voice pitch and perceived infidelity

Biosante to purchase $25.1 million shares of common stock in registered direct offering

Dentists need to take a closer look at potential hazards of exposing patients to zinc

BioSante vaccine increases median survival of resected pancreatic cancer patients

Endo's FORTESTA Gel for treatment of 'Low T' in males is now available in pharmacies

Endo fourth quarter total revenues increase 31% to $511 million

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

Skeleton regulates fertility in males, but not females

Molecular explanation to higher tendency for autism among males

Early balding linked to prostate cancer: Study

Men going bald at young age more likely to develop prostate cancer in later life

State court jury rules in favor of Merck in FOSAMAX trial

FDA waives NDA filing fee for Antares' Anturol NDA

Positive safety data from BioSante's ongoing LibiGel Phase III study in women with HSDD

New study: Testosterone administration leads to significant reduction in mind reading

Acupuncture and exercise help women with PCOS

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Longer life with osteoporosis therapy: Study

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Testosterone News and Research

Latest Testosterone News and Research

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in